Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Ependymoma

INTRODUCTION

Ependymomas are an uncommon group of glial tumors that typically arise within or adjacent to the ependymal lining of the ventricular system [1]. Ependymomas occasionally occur within the brain parenchyma or outside the central nervous system (CNS).

Ependymomas account for less than 10 percent of tumors arising in the central nervous system (CNS) and 25 percent of primary tumors originating in the spinal cord.

The clinical presentation and management of ependymomas arising in the brain will be reviewed here. Ependymomas arising in the spinal cord are discussed separately. (See "Spinal cord tumors".)

EPIDEMIOLOGY

Age and anatomic location — The incidence of ependymomas is approximately equal in males and females. The median age at diagnosis in children is five years of age, and 25 to 40 percent of patients are less than two years old.

The fourth ventricle is the most common infratentorial site and extension into the subarachnoid space occurs frequently, sometimes with encasement of the medulla and upper cervical cord. Supratentorial lesions can be either intraventricular, typically in the lateral ventricles, or parenchymal.

                       

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2014. | This topic last updated: Mar 17, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Shuangshoti S, Rushing EJ, Mena H, et al. Supratentorial extraventricular ependymal neoplasms: a clinicopathologic study of 32 patients. Cancer 2005; 103:2598.
  2. Grill J, Pascal C, Chantal K. Childhood ependymoma: a systematic review of treatment options and strategies. Paediatr Drugs 2003; 5:533.
  3. Ebert C, von Haken M, Meyer-Puttlitz B, et al. Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol 1999; 155:627.
  4. Pollack IF, Mulvihill JJ. Neurofibromatosis 1 and 2. Brain Pathol 1997; 7:823.
  5. Rubio MP, Correa KM, Ramesh V, et al. Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas. Cancer Res 1994; 54:45.
  6. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. Classification of Tumours of the Nervous System, IARC Press, Lyon, France 2007.
  7. Korshunov A, Neben K, Wrobel G, et al. Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. Am J Pathol 2003; 163:1721.
  8. Ellison DW, Kocak M, Figarella-Branger D, et al. Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed 2011; 10:7.
  9. Milde T, Hielscher T, Witt H, et al. Nestin expression identifies ependymoma patients with poor outcome. Brain Pathol 2012; 22:848.
  10. Barton VN, Donson AM, Kleinschmidt-DeMasters BK, et al. Unique molecular characteristics of pediatric myxopapillary ependymoma. Brain Pathol 2010; 20:560.
  11. Rousseau A, Idbaih A, Ducray F, et al. Specific chromosomal imbalances as detected by array CGH in ependymomas in association with tumor location, histological subtype and grade. J Neurooncol 2010; 97:353.
  12. Reardon DA, Entrekin RE, Sublett J, et al. Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma. Genes Chromosomes Cancer 1999; 24:230.
  13. Mazewski C, Soukup S, Ballard E, et al. Karyotype studies in 18 ependymomas with literature review of 107 cases. Cancer Genet Cytogenet 1999; 113:1.
  14. Carter M, Nicholson J, Ross F, et al. Genetic abnormalities detected in ependymomas by comparative genomic hybridisation. Br J Cancer 2002; 86:929.
  15. Yokota T, Tachizawa T, Fukino K, et al. A family with spinal anaplastic ependymoma: evidence of loss of chromosome 22q in tumor. J Hum Genet 2003; 48:598.
  16. Hulsebos TJ, Oskam NT, Bijleveld EH, et al. Evidence for an ependymoma tumour suppressor gene in chromosome region 22pter-22q11.2. Br J Cancer 1999; 81:1150.
  17. Suarez-Merino B, Hubank M, Revesz T, et al. Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3. Neuro Oncol 2005; 7:20.
  18. Huang B, Starostik P, Schraut H, et al. Human ependymomas reveal frequent deletions on chromosomes 6 and 9. Acta Neuropathol 2003; 106:357.
  19. Korshunov A, Witt H, Hielscher T, et al. Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol 2010; 28:3182.
  20. Wani K, Armstrong TS, Vera-Bolanos E, et al. A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol 2012; 123:727.
  21. Yang I, Nagasawa DT, Kim W, et al. Chromosomal anomalies and prognostic markers for intracranial and spinal ependymomas. J Clin Neurosci 2012; 19:779.
  22. Johnson RA, Wright KD, Poppleton H, et al. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 2010; 466:632.
  23. Witt H, Mack SC, Ryzhova M, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 2011; 20:143.
  24. Mack SC, Witt H, Piro RM, et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 2014; 506:445.
  25. Parker M, Mohankumar KM, Punchihewa C, et al. C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature 2014; 506:451.
  26. Pietsch T, Wohlers I, Goschzik T, et al. Supratentorial ependymomas of childhood carry C11orf95-RELA fusions leading to pathological activation of the NF-κB signaling pathway. Acta Neuropathol 2014; 127:609.
  27. Atkinson JM, Shelat AA, Carcaboso AM, et al. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 2011; 20:384.
  28. Prayson RA. Clinicopathologic study of 61 patients with ependymoma including MIB-1 immunohistochemistry. Ann Diagn Pathol 1999; 3:11.
  29. Vanuytsel L, Brada M. The role of prophylactic spinal irradiation in localized intracranial ependymoma. Int J Radiat Oncol Biol Phys 1991; 21:825.
  30. Chen CJ, Tseng YC, Hsu HL, Jung SM. Imaging predictors of intracranial ependymomas. J Comput Assist Tomogr 2004; 28:407.
  31. Maiuri F, Gangemi M, Iaconetta G, et al. Symptomatic subependymomas of the lateral ventricles. Report of eight cases. Clin Neurol Neurosurg 1997; 99:17.
  32. Sun B, Wang C, Wang J, Liu A. MRI features of intramedullary spinal cord ependymomas. J Neuroimaging 2003; 13:346.
  33. Moreno L, Pollack IF, Duffner PK, et al. Utility of cerebrospinal fluid cytology in newly diagnosed childhood ependymoma. J Pediatr Hematol Oncol 2010; 32:515.
  34. Reni M. Guidelines for the treatment of adult intra-cranial grade II-III ependymal tumours. Forum (Genova) 2003; 13:90.
  35. Robertson PL, Zeltzer PM, Boyett JM, et al. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. J Neurosurg 1998; 88:695.
  36. Duffner PK, Krischer JP, Sanford RA, et al. Prognostic factors in infants and very young children with intracranial ependymomas. Pediatr Neurosurg 1998; 28:215.
  37. Healey EA, Barnes PD, Kupsky WJ, et al. The prognostic significance of postoperative residual tumor in ependymoma. Neurosurgery 1991; 28:666.
  38. Timmermann B, Kortmann RD, Kühl J, et al. Combined postoperative irradiation and chemotherapy for anaplastic ependymomas in childhood: results of the German prospective trials HIT 88/89 and HIT 91. Int J Radiat Oncol Biol Phys 2000; 46:287.
  39. Rodríguez D, Cheung MC, Housri N, et al. Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973-2005). J Surg Res 2009; 156:340.
  40. Amirian ES, Armstrong TS, Aldape KD, et al. Predictors of survival among pediatric and adult ependymoma cases: a study using Surveillance, Epidemiology, and End Results data from 1973 to 2007. Neuroepidemiology 2012; 39:116.
  41. Aizer AA, Ancukiewicz M, Nguyen PL, et al. Natural history and role of radiation in patients with supratentorial and infratentorial WHO grade II ependymomas: results from a population-based study. J Neurooncol 2013; 115:411.
  42. Doxey D, Bruce D, Sklar F, et al. Posterior fossa syndrome: identifiable risk factors and irreversible complications. Pediatr Neurosurg 1999; 31:131.
  43. Sanford RA, Kun LE, Heideman RL, Gajjar A. Cerebellar pontine angle ependymoma in infants. Pediatr Neurosurg 1997; 27:84.
  44. Hukin J, Epstein F, Lefton D, Allen J. Treatment of intracranial ependymoma by surgery alone. Pediatr Neurosurg 1998; 29:40.
  45. Palma L, Celli P, Mariottini A, et al. The importance of surgery in supratentorial ependymomas. Long-term survival in a series of 23 cases. Childs Nerv Syst 2000; 16:170.
  46. Rogers L, Pueschel J, Spetzler R, et al. Is gross-total resection sufficient treatment for posterior fossa ependymomas? J Neurosurg 2005; 102:629.
  47. Merchant TE, Fouladi M. Ependymoma: new therapeutic approaches including radiation and chemotherapy. J Neurooncol 2005; 75:287.
  48. Taylor RE. Review of radiotherapy dose and volume for intracranial ependymoma. Pediatr Blood Cancer 2004; 42:457.
  49. Merchant TE, Li C, Xiong X, et al. Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol 2009; 10:258.
  50. Siffert J, Allen JC. Chemotherapy in recurrent ependymoma. Pediatr Neurosurg 1998; 28:314.
  51. Grill J, Le Deley MC, Gambarelli D, et al. Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology. J Clin Oncol 2001; 19:1288.
  52. Chamberlain MC. Salvage chemotherapy for recurrent spinal cord ependymona. Cancer 2002; 95:997.
  53. Gornet MK, Buckner JC, Marks RS, et al. Chemotherapy for advanced CNS ependymoma. J Neurooncol 1999; 45:61.
  54. Bouffet E, Foreman N. Chemotherapy for intracranial ependymomas. Childs Nerv Syst 1999; 15:563.
  55. Fouladi M, Gururangan S, Moghrabi A, et al. Carboplatin-based primary chemotherapy for infants and young children with CNS tumors. Cancer 2009; 115:3243.
  56. Van Poppel M, Klimo P Jr, Dewire M, et al. Resection of infantile brain tumors after neoadjuvant chemotherapy: the St. Jude experience. J Neurosurg Pediatr 2011; 8:251.
  57. Garvin JH Jr, Selch MT, Holmes E, et al. Phase II study of pre-irradiation chemotherapy for childhood intracranial ependymoma. Children's Cancer Group protocol 9942: a report from the Children's Oncology Group. Pediatr Blood Cancer 2012; 59:1183.
  58. van Veelen-Vincent ML, Pierre-Kahn A, Kalifa C, et al. Ependymoma in childhood: prognostic factors, extent of surgery, and adjuvant therapy. J Neurosurg 2002; 97:827.
  59. Grundy RG, Wilne SA, Weston CL, et al. Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol 2007; 8:696.
  60. Sung KW, Lim do H, Lee SH, et al. Tandem high-dose chemotherapy and autologous stem cell transplantation for anaplastic ependymoma in children younger than 3 years of age. J Neurooncol 2012; 107:335.
  61. Needle MN, Goldwein JW, Grass J, et al. Adjuvant chemotherapy for the treatment of intracranial ependymoma of childhood. Cancer 1997; 80:341.
  62. Evans AE, Anderson JR, Lefkowitz-Boudreaux IB, Finlay JL. Adjuvant chemotherapy of childhood posterior fossa ependymoma: cranio-spinal irradiation with or without adjuvant CCNU, vincristine, and prednisone: a Childrens Cancer Group study. Med Pediatr Oncol 1996; 27:8.
  63. Zacharoulis S, Ashley S, Moreno L, et al. Treatment and outcome of children with relapsed ependymoma: a multi-institutional retrospective analysis. Childs Nerv Syst 2010; 26:905.
  64. Merchant TE. Current management of childhood ependymoma. Oncology (Williston Park) 2002; 16:629.
  65. Merchant TE, Boop FA, Kun LE, Sanford RA. A retrospective study of surgery and reirradiation for recurrent ependymoma. Int J Radiat Oncol Biol Phys 2008; 71:87.
  66. Stafford SL, Pollock BE, Foote RL, et al. Stereotactic radiosurgery for recurrent ependymoma. Cancer 2000; 88:870.
  67. Liu AK, Foreman NK, Gaspar LE, et al. Maximally safe resection followed by hypofractionated re-irradiation for locally recurrent ependymoma in children. Pediatr Blood Cancer 2009; 52:804.
  68. Bouffet E, Hawkins CE, Ballourah W, et al. Survival benefit for pediatric patients with recurrent ependymoma treated with reirradiation. Int J Radiat Oncol Biol Phys 2012; 83:1541.
  69. Mason WP, Goldman S, Yates AJ, et al. Survival following intensive chemotherapy with bone marrow reconstitution for children with recurrent intracranial ependymoma--a report of the Children's Cancer Group. J Neurooncol 1998; 37:135.
  70. Brandes AA, Cavallo G, Reni M, et al. A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. Cancer 2005; 104:143.
  71. Green RM, Cloughesy TF, Stupp R, et al. Bevacizumab for recurrent ependymoma. Neurology 2009; 73:1677.
  72. Couec ML, André N, Thebaud E, et al. Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends. Pediatr Blood Cancer 2012; 59:34.
  73. Gururangan S, Fangusaro J, Young Poussaint T, et al. Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study. Neuro Oncol 2012; 14:1404.
  74. Mendrzyk F, Korshunov A, Benner A, et al. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res 2006; 12:2070.
  75. Zavalhia LS, Romitti M, Netto GC, et al. Evaluation of the expression of C-kit (CD117) in ependymomas and oligodendrogliomas. Dis Markers 2012; 33:61.
  76. Mansur DB, Perry A, Rajaram V, et al. Postoperative radiation therapy for grade II and III intracranial ependymoma. Int J Radiat Oncol Biol Phys 2005; 61:387.
  77. McLaughlin MP, Marcus RB Jr, Buatti JM, et al. Ependymoma: results, prognostic factors and treatment recommendations. Int J Radiat Oncol Biol Phys 1998; 40:845.
  78. Bouffet E, Perilongo G, Canete A, Massimino M. Intracranial ependymomas in children: a critical review of prognostic factors and a plea for cooperation. Med Pediatr Oncol 1998; 30:319.
  79. Horn B, Heideman R, Geyer R, et al. A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors. J Pediatr Hematol Oncol 1999; 21:203.
  80. Shu HK, Sall WF, Maity A, et al. Childhood intracranial ependymoma: twenty-year experience from a single institution. Cancer 2007; 110:432.
  81. Korshunov A, Golanov A, Sycheva R, Timirgaz V. The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients. Cancer 2004; 100:1230.
  82. Vanuytsel LJ, Bessell EM, Ashley SE, et al. Intracranial ependymoma: long-term results of a policy of surgery and radiotherapy. Int J Radiat Oncol Biol Phys 1992; 23:313.
  83. Schwartz TH, Kim S, Glick RS, et al. Supratentorial ependymomas in adult patients. Neurosurgery 1999; 44:721.
  84. Schild SE, Nisi K, Scheithauer BW, et al. The results of radiotherapy for ependymomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys 1998; 42:953.
  85. Ernestus RI, Schröder R, Stützer H, Klug N. The clinical and prognostic relevance of grading in intracranial ependymomas. Br J Neurosurg 1997; 11:421.
  86. Ross GW, Rubinstein LJ. Lack of histopathological correlation of malignant ependymomas with postoperative survival. J Neurosurg 1989; 70:31.
  87. Stüben G, Stuschke M, Kroll M, et al. Postoperative radiotherapy of spinal and intracranial ependymomas: analysis of prognostic factors. Radiother Oncol 1997; 45:3.
  88. Reni M, Brandes AA, Vavassori V, et al. A multicenter study of the prognosis and treatment of adult brain ependymal tumors. Cancer 2004; 100:1221.
  89. Metellus P, Barrie M, Figarella-Branger D, et al. Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. Brain 2007; 130:1338.
  90. Armstrong TS, Vera-Bolanos E, Bekele BN, et al. Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience. Neuro Oncol 2010; 12:862.
  91. Vitanovics D, Bálint K, Hanzély Z, et al. Ependymoma in adults: surgery, reoperation and radiotherapy for survival. Pathol Oncol Res 2010; 16:93.
  92. Amirian ES, Armstrong TS, Gilbert MR, Scheurer ME. Predictors of survival among older adults with ependymoma. J Neurooncol 2012; 107:183.
  93. Broniscer A, Ke W, Fuller CE, et al. Second neoplasms in pediatric patients with primary central nervous system tumors: the St. Jude Children's Research Hospital experience. Cancer 2004; 100:2246.
  94. Spiegler BJ, Bouffet E, Greenberg ML, et al. Change in neurocognitive functioning after treatment with cranial radiation in childhood. J Clin Oncol 2004; 22:706.
  95. Duffner PK, Krischer JP, Horowitz ME, et al. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. Ann Neurol 1998; 44:313.
  96. Garwicz S, Anderson H, Olsen JH, et al. Second malignant neoplasms after cancer in childhood and adolescence: a population-based case-control study in the 5 Nordic countries. The Nordic Society for Pediatric Hematology and Oncology. The Association of the Nordic Cancer Registries. Int J Cancer 2000; 88:672.
  97. Stavrou T, Bromley CM, Nicholson HS, et al. Prognostic factors and secondary malignancies in childhood medulloblastoma. J Pediatr Hematol Oncol 2001; 23:431.
  98. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 2001; 93:618.
  99. Devarahally SR, Severson RK, Chuba P, et al. Second malignant neoplasms after primary central nervous system malignancies of childhood and adolescence. Pediatr Hematol Oncol 2003; 20:617.
  100. Armstrong TS, Vera-Bolanos E, Gilbert MR. Clinical course of adult patients with ependymoma: results of the Adult Ependymoma Outcomes Project. Cancer 2011; 117:5133.
  101. Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004; 22:4979.